% OFF
Expires 31 December 2025
CRISPR Cas9 Monoclonal Antibody [7A9]
| Specifications | |
|---|---|
| Type: | Primary Antibody |
| Clonality: | Monoclonal |
| Clone Name: | 7A9 |
| Host: | Mouse |
| Reactivity: | Species Independent |
| Isotype: | IgG1 Kappa |
| Label: | Unconjugated |
| Additional Information | |
|---|---|
| Synonyms: | Anti-Cas9, Anti-CRISPR, Anti-CRISPR/Cas9, CRISPR antibody, Cas9 antibody, Cas9 7A9, 7A9-3A |
Applications
WB, IP, IF, ELISA
Immunogen
Recombinant N-terminal fragment of S. pyogenes Cas9 protein expressed in E. coli.
Purification/Format
Protein G Purified
Background
The discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas9 (CRISPR associated system or CRISPR associated protein 9 nuclease) found in bacteria to work as a defense mechanism against foreign DNA has proven to be an invaluable tool to target and modify a genetic sequence in gene editing and genome engineering applications. The system, known as CRISPR/Cas9, allows for sequence-specific cleavage of a targeted genomic locus by delivering the RNA-guided nuclease (Cas9) and appropriate guide RNAs (gRNA) into a cell. In addition, Protospacer Adjacent Motif (PAM) sequence immediately following the specificity sequence is necessary for successful binding of the Cas9 nuclease.
Product Citations
- Li Z, Guo R, Sun X, Li G, Shao Z, Huo X, Yang R, Liu X, Cao X, Zhang H, Zhang W, Zhang X, Ma S, Zhang M, Liu Y, Yao Y, Shi J, Yang H, Hu C, Zhou Y, Xu C (2024) Engineering a transposon-associated TnpB-ωRNA system for efficient gene editing and phenotypic correction of a tyrosinaemia mouse model. Nat Commun
- Koch J, Neuberger M, Schmidt-Dengler M, Xu J, Carneiro VC, Ellinger J, Kriegmair MC, Nuhn P, Erben P, Michel MS, Helm M, RodrÃguez-Paredes M, Nientiedt M, Lyko F (2023) Reinvestigating the clinical relevance of the m(6)A writer METTL3 in urothelial carcinoma of the bladder. iScience
- Stahl EC, Sabo JK, Kang MH, Allen R, Applegate E, Kim SE, Kwon Y, Seth A, Lemus N, Salinas-Rios V, Soczek KM, Trinidad M, Vo LT, Jeans C, Wozniak A, Morris T, Kimberlin A, Foti T, Savage DF, Doudna JA (2023) Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs. Mol Ther
- Vlasevska S, Garcia-Ibanez L, Duval R, Holmes AB, Jahan R, Cai B, Kim A, Mo T, Basso K, Soni RK, Bhagat G, Dalla-Favera R, Pasqualucci L (2023) KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. Proc Natl Acad Sci U S A
- Giehrl-Schwab J, Giesert F, Rauser B, Lao CL, Hembach S, Lefort S, Ibarra IL, Koupourtidou C, Luecken MD, Truong DJ, Fischer-Sternjak J, Masserdotti G, Prakash N, Ninkovic J, Hölter SM, Vogt Weisenhorn DM, Theis FJ, Götz M, Wurst W (2022) Parkinson's disease motor symptoms rescue by CRISPRa-reprogramming astrocytes into GABAergic neurons. EMBO Mol Med
Price
You save 40 %
516,00 €309,60 €
